The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Human Cells in Mice Provide New Model for Studying HCV

Back to News Homepage

Next

Coming Soon: A Multi-Drug Cocktail for Hepatitis C

Locteron Triumphs in Phase 2 Hepatitis C Trial

November 8, 2010

Print this page

With dosing once every other week, a similar effectiveness as PEG-Intron and fewer side effects, Locteron’s Phase 2B trial is successful.

Positive Results in Phase 2 Locteron Trial

Positive Results in Phase 2 Locteron Trial

Drug Discovery & Development – October 29, 2010

Biolex Therapeutics, Inc. announced positive efficacy, safety and tolerability results from its 72-week SELECT-2 Phase 2b dose-finding Phase 2b trial of Locteron, the company’s lead product candidate for the treatment of hepatitis C. For each of the three Locteron doses tested in SELECT-2, the percentage of patients who maintained undetectable levels of virus at week 60 of the trial, 12 weeks after completion of 48 weeks of treatment (SVR12), were comparable with or exceeded the response rate for the PEG-Intron control. As a result of its controlled-release mechanism, Locteron was dosed half as frequently as PEG-Intron.

Continue reading this entire article:
http://www.dddmag.com/news-Positive-Results-in-Phase-2-Locteron-Trial-102910.aspx

No Comments - be the first!
Share
Share

Previous

Human Cells in Mice Provide New Model for Studying HCV

Back to News Homepage

Next

Coming Soon: A Multi-Drug Cocktail for Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.